Loreev XR (Lorazepam) Patent Expiration, LOE Window & CMS Spending

Loreev XR (Lorazepam) by Almatica: FDA Orange Book LOE 2034-01-08, 10 AB generics, $4.2M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmatica
FDA Application & PathwayN214826 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-01-08
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$4.2M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 56.6% 2-yr change)